Differences in efficacy and indications between larotinib (Vitaika) and entrectinib

Larotrectinib is an oral small molecule TRK inhibitor, mainly used to treat patients with solid tumors carrying NTRK gene fusions. Its mechanism of action is to inhibit tumor cell growth by selectively inhibiting TRK receptor tyrosine kinase and blocking tumor cell proliferation and survival signals. Entrectinib (Entrectinib) is also a TRK inhibitor, but has a broader targeting spectrum, in addition to TRKin addition to receptors, it can also inhibit the growth of tumors with ROS1 and ALK mutations.

Larotinib is mainly suitable for NTRK fusion-positive adult and pediatric solid tumor patients. It is a precise targeted therapy drug that is independent of tumor tissue. In contrast, entrectinib is approved for patients with ROS1-positive non-small cell lung cancer (NSCLC) in addition to NTRK fusion-positive tumors. This means that the indications of entrectinib are broader and can cover some patients with driver gene mutations other than TRK.

Clinical studies have shown that larotrectinib has a high objective response rate (ORR) and durable response in patients with NTRK fusion-positive tumors, especially in pediatric patients. Entrectinib is also effective in patients with NTRK fusion, but its multi-target characteristics enable it to also achieve good therapeutic responses in patients with ROS1 positive lung cancer. Overall, larotrectinib is more focused on the TRK target, while entrectinib has a wider range of efficacy.

In clinical practice, for patients who are clearly positive for NTRK fusion, larotrectinib and entrectinib can be used as the first-choice targeted drugs, but the selection needs to be based on the patient's age, tumor type and combined gene mutations. If the patient has ROS1 positivity or other driver gene mutations, entrectinib may be more advantageous. In addition, drug tolerance, side effect profile, and dosing regimen need to be considered in individualized treatment to achieve optimal efficacy and safety.

Reference link:https://www.drugs.com